HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. (OTC: IPXL) today announced that due to urgent priorities associated with the recent revocation of the registration of the Company’s common stock under section 12(g) of the Securities and Exchange Act of 1934, the Company finds it necessary to cancel its previously announced presentation at the UBS Global Specialty and Generic Pharmaceuticals Conference on Thursday, May 29th, at 10:00 a.m. London GMT (5:00 a.m. ET).
